Renaissance Technologies
KDNY

Renaissance Technologies’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Renaissance Technologies’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-116,562
Closed -$2.7M – 4390
2023
Q1 		$2.7M Sell
116,562
-65,100
-36% -$1.55M ﹤0.01% 1839
2022
Q4 		$4.76M Sell
181,662
-37,680
-17% -$835K 0.01% 1554
2022
Q3 		$4.31M Sell
219,342
-53,620
-20% -$1.08M 0.01% 1526
2022
Q2 		$4.77M Buy
272,962
+6,220
+2% +$97.6K 0.01% 1598
2022
Q1 		$4.36M Sell
266,742
-101,900
-28% -$1.39M 0.01% 1698
2021
Q4 		$6.01M Sell
368,642
-162,920
-31% -$2.32M 0.01% 1402
2021
Q3 		$6.78M Sell
531,562
-113,580
-18% -$1.49M 0.01% 1274
2021
Q2 		$9.11M Sell
645,142
-96,700
-13% -$1.55M 0.01% 1240
2021
Q1 		$11.5M Sell
741,842
-94,244
-11% -$1.54M 0.01% 1098
2020
Q4 		$13.3M Sell
836,086
-40,716
-5% -$614K 0.01% 981
2020
Q3 		$10.7M Sell
876,802
-52,060
-6% -$698K 0.01% 1084
2020
Q2 		$10.7M Buy
928,862
+18,900
+2% +$261K 0.01% 1174
2020
Q1 		$12.5M Sell
909,962
-17,700
-2% -$209K 0.01% 1024
2019
Q4 		$5.47M Buy
927,662
+380,022
+69% +$2.07M ﹤0.01% 1794
2019
Q3 		$2.9M Buy
547,640
+185,200
+51% +$1.23M ﹤0.01% 2074
2019
Q2 		$2.79M Buy
362,440
+130,720
+56% +$1.99M ﹤0.01% 2158
2019
Q1 		$4.61M Buy
231,720
+158,720
+217% +$2.77M ﹤0.01% 1857
2018
Q4 		$964K Buy
+73,000
New +$1.46M ﹤0.01% 2590
2018
Q3 		– Sell
-11,800
Closed -$413K – 3624
2018
Q2 		$413K Sell
11,800
-35,660
-75% -$1.37M ﹤0.01% 2888
2018
Q1 		$2.21M Sell
47,460
-15,300
-24% -$560K ﹤0.01% 2276
2017
Q4 		$2.35M Sell
62,760
-23,420
-27% -$1.02M ﹤0.01% 2253
2017
Q3 		$4.59M Buy
86,180
+35,440
+70% +$2.11M 0.01% 1829
2017
Q2 		$2.89M Buy
50,740
+14,360
+39% +$721K ﹤0.01% 2052
2017
Q1 		$1.96M Buy
36,380
+32,160
+762% +$1.82M ﹤0.01% 2252
2016
Q4 		$241K Buy
+4,220
New +$255K ﹤0.01% 2950
2016
Q1 		– Sell
-6,920
Closed -$974K – 3581
2015
Q4 		$974K Buy
+6,920
New +$940K ﹤0.01% 2472

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies's KDNY Position: Q2 2023 in Review

Renaissance Technologies sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 116,562 shares — an estimated $2.7M sold.

Renaissance Technologies first reported a position in KDNY in Q4 2015 and held it in 26 quarters. The position peaked at $13.3M in Q4 2020. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

  • Renaissance Technologies reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Renaissance Technologies sold 116,562 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.7M.
  • Renaissance Technologies first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 26 quarters.
  • Renaissance Technologies's Chinook Therapeutics, Inc. Common Stock position peaked at $13.3M in Q4 2020.
  • 185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.